Biocon Chairperson Accidental Entrepreneur Story

Biocon Chairperson Accidental Entrepreneur Story
Biocon Chairperson Accidental Entrepreneur Story
Spread the love

Yes, we are going to see about Kiran Mazumdar-Shaw who is a Biocon Chairperson Accidental Entrepreneur Story. In this blog, we are going to see about her journey, successes as well as failures he faced in his journey.


The journey begins with Padma Shri Kiran Mazumdar-Shaw who created a revolution in the field of the pharmaceutical industry. It started in 1978 were Kiran Mazumdar-Shaw was applying for a job and he fails to get it who holds a degree from Australia, at that time Biocon Chairperson Accidental Entrepreneur Story she faced many difficulties while getting a job but accidentally he meets an Irish biotech entrepreneur who told her that he wants to start a company in India.

I also heard a lot about you from Australia if you become a partner I can start the company in India where she told me that I am not the right partner because I don’t have the capital as well as any business experience. Biocon Chairperson Accidental Entrepreneur Story I am just in search of a job where he said that he has the skill of entrepreneurship you can take a try then she taught me that this is an opportunity and she has to use that in a great manner.

Biocon Company Overview:

Kiran Mazumdar-Shaw Image
Biocon Chairperson Kiran Mazumdar-Shaw (Image Source: cnbctv.18)

Biocon is a global biopharmaceutical company changing lives in over 120 countries by finding new and Biocon Chairperson Accidental Entrepreneur Story affordable ways to treat diabetes, cancer, etc. The company was started in 1978 with the mission to make a medicine that can be used by a minimum of 100 crore people their Biocon Chairperson Accidental Entrepreneur Story main priorities are PATIENT CENTRICITY, FOCUS ON SCIENCE, ACCESS TO ALL, QUALITY FIRST, and PEOPLE POWER.

See also  Digit Insurance: Case Study, Company Profile, Founder, Investors, Competitors, and many more
Company nameBIOCON
FoundersKiran Mazumdar-Shaw
Started at1978
CompetitorsEMS Pharma, Cipla, Sun Pharma, and Idorsia
RevenueFY22 Revenue at Rs 8,397 Cr

Biocon History:

Biocon was founded in 1978 with Rs.10,000 as the initial capital and the age of Kiran Mazumdar-Shaw was just 25 years. Biocon Chairperson Accidental Entrepreneur Story and 1979 – Becomes the first Indian company to manufacture and export enzymes to the US and Europe. 1989 – Unilever acquires Biocon Biochemicals Ltd.

She started the company in an unknown territory with high financial risk because at that time the word biochemical was not so famous, Biocon Chairperson Accidental Entrepreneur Story so the banks are not ready to provide loans to the company also because she has no consolidation to keep.

Biocon logo
Biocon (Image Source:

Biocon Struggles:

  • Banks are not ready to provide loans because she does not have any collateral to keep.
  • While taking interviews the interviewers are not ready to work under a woman because she was the boss and also, Biocon Chairperson Accidental Entrepreneur Story and they are afraid for their job security.
  • She was suffering from both capital and manpower, but times changed.

Biocon Success:

There is the fact that after the dark bright appears, here are a few achievements she earned.

  • India’s Top 5 powerful women
  • World’s Top 25 powerful women
  • Medicine – 100 crore people
  • Market Cap – 31000 crore
  • Turnover – 6000 crore
  • Employees – 12000
  • Research Scientists
  • In 1978 – Fastest Billionaire

Biocon Awards:


Biocon On Nowadays:

The company nowadays is considered as a top 3 organization in the field of the pharmaceutical industry with a market capitalization of 31000 crores.

See also  Miro - Startup Story | Founder| CEO | Funding | History | Competitors

Biocon’s core philosophy is based on research lead as well as creating a vast opportunity for the scientists.

Biocon image
Biocon (image Source:

Biocon Board of Directors:

The team members of Biocon are listed below:

1.Executive ChairpersonKIRAN MAZUMDAR SHAW
2.CEO and Managing DirectorSIDDHART MITTAL
3.Non-Executive DirectorRAVI MAZUMDAR
4.Independent and Non-Executive DirectorVIJAY KUCHROO
5.Independent and Non-Executive DirectorBOBBY KANUBHAI PARIKH
6.Independent and Non-Executive DirectorM.DAMODARAN
7.Non-Executive DirectorERIC MAZUMDAR
8.Independent and Non-Executive DirectorNAINA LAL KIDWAI

Biocon Management Team:

1.Executive Chairperson
Biocon Limited and
Biocon Biologics Limited
2.Managing Director
Biocon Biologics Limited
3.CEO & Managing Director
Biocon Limited
4.Deputy Chief Executive Officer
Biocon Biologics Limited
5.CEO & Managing Director
Syngene International

Biocon Employees:

The company Biocon created a number of opportunities for researchers who are interested in the field of pharmaceuticals. The company Biocon Chairperson Accidental Entrepreneur Story has provided employability to12000 employees among them there are 6000 scientists were employed.

Biocon Products:

The company Biocon created a number of products that fills the global medical need, their products as classified into different categories,

  • Generics
  • Biosimilars
  • Branded Formulation
  • Novel biologics
Biocon image
Biocon (Image Source:

Biocon Generic Formulations:

Sl. NoMolecule NameStatus
1RosuvastatinCommercial (United States, Europe)
2SimvastatinCommercial (United States)
3AtorvastatinCommercial (United States)
4FingolimodApproved (United States, Europe)
5DapagliflozinTentative Approval (United States)
6PemetrexedTentative Approval (United States)
7TacrolimusCommercial (United States)
8Everolimus (RLD Affinitor)Commercial (United States), Approved (Europe)
9PravastatinCommercial (United States)
10LabetalolCommercial (United States)
11EsomeprazoleCommercial (United States)
12PosaconazoleCommercial (United States)

Biocon API:

Sl. NoCardiology (Molecule Name)
Sl. NoAnti-Diabetics (Molecule Name)
3Sitagliptin (various salts)
4Dapagliflozin (different solvate forms)
Sl. NoImmunosuppressants (Molecule Name)
5Mycophenolate Mofetil (MMF)
6Mycophenolate Sodium (MPS)
Sl. NoMultiple Sclerosis (Molecule Name)
1Glatiramer Acetate
Sl. NoAnti-Cancer/Oncology (Molecule Name)
Sl. NoOther Key Products (Molecule Name)

Biocon Achievements and Milestones:

As a company, it is easy to keep a milestone, but it is hard to achieve it, Biocon has achieved a number of milestones in the recent 44 years.

See also  3 benefits of networking for entrepreneurs
1.Biocon’s Founding Day1978
2.First export of Papain, a plant enzyme derived from Papaya1979
3.Biocon’s groundbreaking of its heritage campus on 20th KM, Hosur Road, Bangalore1980
4.Biocon starts construction at its own site1981
5.Biocon’s Bangalore campus is inaugurated1983
6.R&D division established to develop Solid State Enzyme Fermentation Technology1984
7.Unilever Acquires Biocon’s Irish Parent1989
8.Scaling up indigenous fermentation technology1990
9.First Life Sciences Company from India to get ISO 9001 Certification1993
10.Biocon establishes Syngene International Pvt. Ltd1994
11.Biocon Quest India Ltd (BQIL) is established1995
12.Biocon becomes an independent entity1998
13.Nobel Laureate Prof. James D Watson visits Biocon1999
14.Clinigene – India’s first Clinical Research Services Organization2000
15.Biocon’s proprietary bioreactor, PlaFractor, is commissioned2000
16.First fully automated submerged fermentation plant commissioned2000
17.First company globally to be approved by U.S. FDA to sell Lovastatin API2001
18.Patent granted for proprietary PlaFractor technology2001
19.Biocon Biopharmaceuticals established as a JV with CIMAB, Cuba2002
20.World’s first Pichia-based rh-Insulin developed and commercialized in India2004
21.Biocon makes a resounding debut on the Indian stock market2004
22.Biocon Park, India’s first private Biotechnology SEZ, inaugurated2006
23.First company in India to launch a novel biologic, Nimotuzumab2006
24.India’s largest multi-product Biologics facility inaugurated2006
25.Biocon divests enzymes business2007
26.Biocon acquires stake in AISCorp. GmbH, a German pharmaceutical company2008
27.Biocon, Mylan enter strategic global partnership for development of biosimilars2009
28.Biocon launches Basalog® (Insulin Glargine) in India2009
29.Biocon Bristol-Myers Squibb Research Centre (BBRC) inaugurated2009
30.Biocon and Pfizer enter into a strategic global agreement2010
31.Biocon starts work on the largest integrated insulins facility in Asia2011
32.Biocon launches INSUPen® for patients in India2011
33.Biocon Research Centre Inaugurated2012
34.The world’s first anti-CD6 monoclonal antibody Itolizumab commercialized in India2013
35.Biocon House inaugurated2013
36.Biocon establishes Biocon Academy under its CSR agenda2013
37.Biocon introduces the world’s first biosimilar Trastuzumab, CANMAb™, in India2014
38.Syngene debuts on the Indian stock market2015
39.Biocon’s new insulin devices facility inaugurated in Bangalore2015
40.Biocon Gets its First Generic Formulation Approval in the EU2016
41.First biosimilar from India to be approved in Japan2016
42.First company from India to get U.S. FDA approval for a biosimilar2017
43.Biocon’s first overseas facility in Malaysia starts operations2017
44.Biocon out licenses Itolizumab to Equillium for U.S., Canada2017
45.Biocon launches its biosimilar Bevacizumab in India2017
46.First company from India to have biosimilar commercialized in the U.S.2018
47.Semglee is the first biosimilar from Biocon & Mylan’s joint insulins portfolio to be approved in Europe2018
48.Biocon, Sandoz enter global partnership for next-gen biosimilars2018
49.Two biosimilars get marketing authorization in the EU2018
50.Biosimilars business consolidated under the independent entity Biocon Biologics2019
51.Ogivri, biosimilar Trastuzumab, commercialized in the U.S2019
52.Bicara Therapeutics incorporated to advance novel immuno-oncology assets2019
53.True North makes a primary equity investment in Biocon Biologics2020
54.Itolizumab Gets DCGI Nod for Restricted Emergency Use in Moderate to Severe COVID-19 Patients2020
55.Tata Capital picks up a minority stake in Biocon Biologics2020
56.Semglee™ (insulin glargine injection) Launched in the U.S.2020
57.Biocon Biologics Receives USD 150 Million Capital Injection from Goldman Sachs2020
58.Biocon Biologics Receives USD 75 Million Capital Injection from ADQ2021
59.Biocon Biologics Partners with Adagio Therapeutics to Advance Antibody for the Prevention and Treatment of COVID-192021
60.Semglee® Receives Historic U.S. Approval for First Interchangeable Biosimilar2021
61.Biocon Biologics and Serum Institute Life Sciences Enter Strategic Alliance2021
62.Biocon Enters Prestigious Dow Jones Sustainability Emerging Markets Index2021
63.Biocon Biologics Inks Deal to Acquire Viatris’ Global Biosimilars Business for up to USD 3.335 billion2022

FAQs about Biocon Chairperson Accidental Entrepreneur Story:

How Kiran Mazumdar-Shaw started her business?

She started Biocon India in 1978 in the garage of her rented house in Bengaluru with a seed capital of Rs. 10,000. Biocon Chairperson Accidental Entrepreneur Story and Although it was a joint venture, Indian laws restricted foreign ownership to only 30% of the company, which meant that 70% of the company belonged to Kiran Mazumdar Shaw.

What are the challenges faced by Kiran Mazumdar-Shaw?

Her Struggles. Biocon Chairperson Accidental Entrepreneur Story “I faced a number of challenges whilst I built Biocon. Initially, Biocon Chairperson Accidental Entrepreneur Story I had credibility challenges where I couldn’t get banks to fund me; I couldn’t recruit people to work for a woman boss. Even in the businesses where I had to procure raw materials, they didn’t want to deal with women.”

Who was the chair person of Biocon?

Executive Chairperson – Biocon Limited and Biocon Biologics Limited. Kiran Mazumdar-Shaw is a first-generation entrepreneur Biocon Chairperson Accidental Entrepreneur Story and global business leader with over 4 decades of experience in biotechnology. Fueled by her passion, she started her biotech journey in 1978 from her garage in India.

Who are real leaders according to Kiran Mazumdar-Shaw?

According to Kiran Mazumdar-Shaw, true leaders are visionaries with a sense of purpose, who persevere and have a passion for change. Biocon Chairperson Accidental Entrepreneur Story They know that leadership is not about control but being able to inspire people with values and vision. Real leaders are those who spot opportunities where others see challenges.

How much is Kiran Mazumdar-Shaw worth?

Kiran Mazumdar-Shaw’s worth is 250 crores USD.

What happened when Kiran returned to India after completing her education in Australia?

Upon graduating, she held a string of jobs including that of a trainee brewer at Carlton and United Breweries as well as a trainer master Biocon Chairperson Accidental Entrepreneur Story at Barret Brothers and Burston in Australia. Upon enhancing her skills, she moved back to India wherein she worked as a trainee consultant at Jupiter Breweries in Calcutta.

How old is Kiran Mazumdar-Shaw?

Kiran Mazumdar-Shaw age is 69 years.

What is Biocon known for?

World’s first Pichia-based RH-Insulin developed and commercialized in India. Biocon is the first company in the world to commercialize Biocon Chairperson Accidental Entrepreneur Story recombinant human insulin (RH-insulin), Insugen®, using a novel Pichia pastoris yeast expression system. Today, Biocon’s RH-insulin is approved in over 40 countries.

What is the tagline for Biocon?

Biocon – India’s largest biopharmaceutical company. Hope. saves lives.

Why do you want to join Biocon?

Working with one of the world’s most advanced biopharmaceutical companies brings with it a tremendous Biocon Chairperson Accidental Entrepreneur Story opportunity to create a lasting impact on global health. Our strategy is to provide affordable access to a specialty portfolio of medicines for global patient populations.


Biocon Chairperson Accidental Entrepreneur Story is working on the vision to provide medicines to people at a cost-effective price because they know how people suffer from chronic or other diseases and because of the high cost of the medicines many peoples are not getting treated.

Spread the love

Sai Sandhya